GlaxoSmithKline has agreed to pay $750 million to settle federal charges in the fourth-largest health care fraud settlement in the U.S. The deal calls for GSK to plead guilty to introducing four types of adulterated drugs for delivery into interstate commerce from March 2003 to October 2004. The drugs were made by subsidiary SB Pharma Puerto Rico at a since-closed facility

After sifting through a plaintiff’s “hydra-like” complaint, a New York federal judge has dismissed a putative class action alleging that American Express and two executives made false and misleading statements to investors about the types of credit risk the company faced as it tried to expand its share of the credit card market beyond its traditional high-end clientele.

“You’re so lucky you work for yourself; you don’t have to work with people like [fill in the blank].” Solo practitioner Paul Schorn hears this often from friends in midsize and large firms, and in his heart, he knows they’re right: Part of what makes solo practice worthwhile is getting to avoid some of the people who can drain all the fun out of practicing law. Here are four types of people Schorn is happy not to face on a daily basis, along with the lessons he believes people can learn from them.

The Am Law world got to flex its muscles Wednesday when the Federal Deposit Insurance Corporation backed off of stringent proposed rules that would have governed private equity investment in failed banks. Am Law’s biggest names had submitted letter after letter urging the FDIC to back off the regulations and arguing that the proposed rules discriminated against private equity firms by setting higher standards for them than for other types of investors.